Company

Novo Nordisk

NYSE:NVO

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

227 stories · page 3 of 12

Pharma & Biotech

Inside Biotech: Novo Nordisk cuts GLP-1 prices as pressure builds on obesity juggernaut

By Proactive 25/02

Pharma & Biotech

Anthropic's enterprise showcase impressed the room but is the AI threat to software stocks remains largely a ghost story?

By Proactive 24/02

Pharma & Biotech

Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound

By Proactive 24/02

Pharma & Biotech

Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value

By Proactive 23/02

Pharma & Biotech

Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint

By Proactive 19/02

Pharma & Biotech

Novo Nordisk plans Wegovy vials amid obesity-drug competition

By Proactive 12/02

Pharma & Biotech

Novo Nordisk target cut by Deutsche Bank despite long-term optimism

By Proactive 11/02

Pharma & Biotech

Hims & Hers scraps low-cost weight-loss pill following backlash

By Proactive 09/02

Pharma & Biotech

Citi flags lingering risks to Novo despite strong weight-loss portfolio

By Proactive 06/02

Pharma & Biotech

Hims & Hers launches compounded semaglutide pill as lower-cost weight loss option

By Proactive 05/02

Nasdaq closes deep in the red while Dow climbs with Alphabet earnings on deck

Traders continue to mull the possible effects of AI on a range of sectors

By Proactive 04/02

Pharma & Biotech

Novo Nordisk: Pfizer weight loss drug offers credible new competition

By Proactive 04/02

Pharma & Biotech

Novo Nordisk warns of 2026 sales decline, shares fall

By Proactive 03/02

Pharma & Biotech

Citi flags bigger tests ahead after Novo Nordisk diabetes trial success

By Proactive 03/02

Pharma & Biotech

Novo Nordisk obesity pill unlikely to impress early, UBS warns

By Proactive 15/01

Pharma & Biotech

Inside Biotech: Novo Nordisk’s Wegovy pill hits US market as obesity drug war advances

By Proactive 06/01

Pharma & Biotech

Novo Nordisk launches first oral GLP-1 weight loss pill in the US

By Proactive 05/01

Pharma & Biotech

Novo Nordisk surges as US approves first weight-loss pill

By Proactive 23/12/2025

Pharma & Biotech

AstraZeneca is top pharma tip for 2026, with GSK left trailing

By Proactive 08/12/2025

Pharma & Biotech

Inside Biotech: TGA raises a red flag on GLP-1 drugs — but uncertainty remains

By Proactive 03/12/2025